Article History
Received: 18 November 2019
Accepted: 9 March 2020
First Online: 9 April 2020
Competing interests
: J.M.V. declares no conflict of interests. Both G.V.L. and C.U.B. declare no direct conflicts with this work. For unrelated conflicts, G.V.L. is a consultant advisor to Aduro, Amgen, BMS, Mass-Array, Pierre-Fabre, Novartis, MERCK MSD and Roche. C.U.B. has received research funding from BMS, Novartis and NanoString; has an advisory role for BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre and Third Rock Ventures; and is a stock owner of Uniti Cars, Neon Therapeutics and Forty Seven.